Cardiovascular Toxicology

, Volume 14, Issue 1, pp 30–40 | Cite as

Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment

  • Luciana Grazziotin Rossato
  • Vera Marisa Costa
  • Eliane Dallegrave
  • Marcelo Arbo
  • Renata Silva
  • Rita Ferreira
  • Francisco Amado
  • Ricardo Jorge Dinis-Oliveira
  • José Alberto Duarte
  • Maria de Lourdes Bastos
  • Carlos Palmeira
  • Fernando Remião
Article

Abstract

Mitoxantrone (MTX) is a chemotherapeutic agent, which presents late irreversible cardiotoxicity. This work aims to highlight the mechanisms involved in the MTX-induced cardiotoxicity, namely the effects toward mitochondria using in vivo and in vitro studies. Male Wistar rats were treated with 3 cycles of 2.5 mg/kg MTX at day 0, 10, and 20. One treated group was euthanized on day 22 (MTX22) to evaluate the early MTX cardiac toxic effects, while the other was euthanized on day 48 (MTX48), to allow the evaluation of MTX late cardiac effects. Cardiac mitochondria isolated from 4 adult untreated rats were also used to evaluate in vitro the MTX (10 nM, 100 nM, and 1 μM) direct effects upon mitochondria functionality. Two rats of MTX48 died on day 35, and MTX treatment caused a reduction in relative body weight gain in both treated groups with no significant changes in water and food intake. Decreased levels of plasma total creatine kinase and CK-MB were detected in the MTX22 group, and increased plasma levels of lactate were seen in MTX48. Increased cardiac relative mass and microscopic changes were evident in both treated groups. Considering mitochondrial effects, for the first time, it was evidenced that MTX induced an increase in the complex IV and complex V activities in MTX22 group, while a decrease in the complex V activity was accompanied by the reduction in ATP content in the MTX48 rats. No alterations in mitochondria transmembrane potential were found in isolated mitochondria from MTX48 rats or in isolated mitochondria directly incubated with MTX. This study highlights the relevance of the cumulative MTX-induced in vivo mitochondriopathy to the MTX cardiotoxicity.

Keywords

Mitoxantrone Cardiotoxicity Mitochondria 

Abbreviations

ATP

Adenosine 5′-triphosphate

AST

Aspartate aminotransferase

BN-PAGE

Blue native polyacrylamide gel electrophoresis

CK

Creatine kinase

DAB

Diaminobenzidine

DTNB

5,5-Dithio-bis(2-nitrobenzoic acid)

GSH

Reduced glutathione

GSHt

Total glutathione

GSSG

Oxidized glutathione

HClO4

Perchloric acid

LDH

Lactate dehydrogenase

MTX

Mitoxantrone

β-NADPH

Reduced β-nicotinamidephosphate adenine dinucleotide

TPP+

Tetraphenylphosphonium

Notes

Acknowledgments

This work was supported by the Fundação para a Ciência e Tecnologia (FCT)—project (EXPL/DTP-FTO/0290/2012)—QREN initiative with EU/FEDER financing through COMPETE—Operational Programme for Competitiveness Factors. LGR, VMC, and RJD-O thank FCT for their PhD Grant (SFRH/BD/63473/2009) and Post-doc Grants (SFRH/BPD/63746/2009) and (SFRH/BPD/36865/2007), respectively. The authors are grateful to Fundação para a Ciência e Tecnologia for grant no. Pest C/EQB/LA0006/2011.

References

  1. 1.
    Seiter, K. (2005). Toxicity of the topoisomerase II inhibitors. Expert Opinion on Drug Safety, 4, 219–234.PubMedCrossRefGoogle Scholar
  2. 2.
    Kingwell, E., Koch, M., Leung, B., Isserow, S., Geddes, J., Rieckmann, P., et al. (2010). Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 74, 1822–1826.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Avasarala, J. R., Cross, A. H., Clifford, D. B., Singer, B. A., Siegel, B. A., & Abbey, E. E. (2003). Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Multiple Sclerosis, 9, 59–62.Google Scholar
  4. 4.
    Canal, P., Attal, M., Chatelut, E., Guichard, S., Huguet, F., Muller, C., et al. (1993). Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Research, 53, 4850–4854.PubMedGoogle Scholar
  5. 5.
    Ehninger, G., Schuler, U., Proksch, B., Zeller, K. P., & Blanz, J. (1990). Pharmacokinetics and metabolism of mitoxantrone. A review. Clinical Pharmacokinetics, 18, 365–380.PubMedCrossRefGoogle Scholar
  6. 6.
    Batra, V. K., Morrison, J. A., Woodward, D. L., Siverd, N. S., & Yacobi, A. (1986). Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metabolism Reviews, 17, 311–329.PubMedCrossRefGoogle Scholar
  7. 7.
    Rossato, L., Costa, V. M., De Pinho, P., Freitas, V., Viloune, L., Bastos, M., et al. (2013). The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Archives of Toxicology, 10, 1809–1820. doi: 10.1007/s00204-013-1040-6.
  8. 8.
    Rossato, L. G., Costa, V. M., Villas-Boas, V., de Lourdes Bastos, M., Rolo, A., Palmeira, C., et al. (2013). Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier effect. Cardiovascular Toxicology. doi: 10.1007/s12012-013-9224-0.
  9. 9.
    Shipp, N. G., Dorr, R. T., Alberts, D. S., Dawson, B. V., & Hendrix, M. (1993). Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Research, 53, 550–556.PubMedGoogle Scholar
  10. 10.
    Alderton, P. M., Gross, J., & Green, M. D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Research, 52, 194–201.PubMedGoogle Scholar
  11. 11.
    Bachmann, E., Weber, E., & Zbinden, G. (1987). Effect of mitoxantrone and doxorubicin on energy metabolism of the rat heart. Cancer Treatment Reports, 71, 361–366.PubMedGoogle Scholar
  12. 12.
    Padrão, A. I., Ferreira, R. M. P., Vitorino, R., Alves, R. M. P., Neuparth, M. J., Duarte, J. A., et al. (2011). OXPHOS susceptibility to oxidative modifications: The role of heart mitochondrial subcellular location. Biochimica et Biophysica Acta, 1807, 1106–1113.PubMedCrossRefGoogle Scholar
  13. 13.
    Pontes, H., Duarte, J. A., De Pinho, P. G., Soares, M. E., Fernandes, E., Dinis-Oliveira, R. J., et al. (2008). Chronic exposure to ethanol exacerbates MDMA-induced hyperthermia and exposes liver to severe MDMA-induced toxicity in CD1 mice. Toxicology, 252, 64–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Rossato, L. G., Costa, V. M., De Pinho, P. G., Carvalho, F., Bastos, M. L., & Remião, F. (2011). Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes. Archives of Toxicology, 85, 929–939.PubMedCrossRefGoogle Scholar
  15. 15.
    Barbosa, D. J., Capela, J. P., Oliveira, J. M., Silva, R., Ferreira, L. M., Siopa, F., et al. (2012). Pro-oxidant effects of ecstasy and its metabolites in mouse brain synaptosomes. British Journal of Pharmacology, 165, 1017–1033.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Lowry, O., & Rosebrough, N. (1951). Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–272.PubMedGoogle Scholar
  17. 17.
    Rolo, A. P., Oliveira, P. J., Moreno, A. J., & Palmeira, C. M. (2000). Bile acids affect liver mitochondrial bioenergetics: Possible relevance for cholestasis therapy. Toxicological Sciences, 57, 177–185.PubMedCrossRefGoogle Scholar
  18. 18.
    Duarte, F. V., Simões, A. M., Teodoro, J. S., Rolo, A. P., & Palmeira, C. M. (2011). Exposure to dibenzofuran affects lung mitochondrial function in vitro. Toxicology Mechanisms and Methods, 21, 571–576.PubMedCrossRefGoogle Scholar
  19. 19.
    Patten, R. D., & Hall-Porter, M. R. (2009). Small animal models of heart failure: Development of novel therapies, past and present. Circulation, 2, 138–144.PubMedGoogle Scholar
  20. 20.
    Novak, R. F., & Kharasch, E. D. (1985). Mitoxantrone: Propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity. Investigational New Drugs, 3, 95–99.PubMedCrossRefGoogle Scholar
  21. 21.
    Kharasch, E. D., & Novak, R. F. (1983). Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation. Journal of Pharmacology and Experimental Therapeutics, 226, 500–506.PubMedGoogle Scholar
  22. 22.
    Ingwall, J. S., & Weiss, R. G. (2004). Is the failing heart energy starved? On using chemical energy to support cardiac function. Circulation Research, 95, 135–145.PubMedCrossRefGoogle Scholar
  23. 23.
    Ventura-Clapier, R., Garnier, A., & Veksler, V. (2004). Energy metabolism in heart failure. Journal of Physiology, 555, 1–13.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Luft, F. C. (2001). Lactic acidosis update for critical care clinicians. Journal of the American Society of Nephrology, 12, S15–S19.PubMedGoogle Scholar
  25. 25.
    Dzeja, P. P., Redfield, M. M., Burnett, J. C., & Terzic, A. (2000). Failing energetics in failing hearts. Current Cardiology Reports, 2, 212–217.PubMedCrossRefGoogle Scholar
  26. 26.
    Kluza, J., Marchetti, P., Gallego, M.-A., Lancel, S., Fournier, C., Loyens, A., et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene, 23, 7018–7030.PubMedCrossRefGoogle Scholar
  27. 27.
    Khan, S. N., Lai, S. K., Kumar, P., & Khan, A. U. (2010). Effect of mitoxantrone on proliferation dynamics and cell cycle progression. Bioscience Reports, 30, 375–381.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Luciana Grazziotin Rossato
    • 1
  • Vera Marisa Costa
    • 1
  • Eliane Dallegrave
    • 1
    • 2
  • Marcelo Arbo
    • 1
  • Renata Silva
    • 1
  • Rita Ferreira
    • 3
  • Francisco Amado
    • 8
  • Ricardo Jorge Dinis-Oliveira
    • 1
    • 4
    • 7
  • José Alberto Duarte
    • 5
  • Maria de Lourdes Bastos
    • 1
  • Carlos Palmeira
    • 6
  • Fernando Remião
    • 1
  1. 1.REQUIMTE, Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de FarmáciaUniversidade do PortoPortoPortugal
  2. 2.Universidade Federal de Ciências da Saúde de Porto AlegrePorto AlegreBrazil
  3. 3.QOPNA, Departamento de QuímicaUniversidade de AveiroAveiroPortugal
  4. 4.Departamento de Medicina Legal e Ciências Forenses, Faculdade de MedicinaUniversidade do PortoPortoPortugal
  5. 5.CIAFEL, Faculdade de DesportoUniversidade do PortoPortoPortugal
  6. 6.Centro de Neurociências e Biologia Celular de Coimbra, Departamento de Ciências da VidaUniversidade de CoimbraCoimbraPortugal
  7. 7.Department of Sciences, Advanced Institute of Health Sciences - NorthCESPU, CRLGandraPortugal
  8. 8.Escola Superior de Saúde, Universidade de Aveiro (ESSUA)AveiroPortugal

Personalised recommendations